Folotyn for Non-Hodgkin's Lymphoma Salisbury MD

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Bennett W Yu
(410) 749-1282
145 E Carroll St
Salisbury, MD
Specialty
Hematology / Oncology

Data Provided by:
Gail C.s. Anderson
(410) 860-9805
100 E Carroll St
Salisbury, MD
Specialty
Radiation Oncology

Data Provided by:
Robert Louis Clinton, MD
145 E Carroll St
Salisbury, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Md Sch Of Med, Baltimore Md 21201
Graduation Year: 1985

Data Provided by:
Jennifer Jo Morgan, MD
(410) 546-5277
Salisbury, MD
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Howard Univ Coll Of Med, Washington Dc 20059
Graduation Year: 1998

Data Provided by:
Joseph Anthony Grasso Jr, MD
(410) 749-1282
145 E Carroll St Ste A-3
Salisbury, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Di Bologna, Fac Di Med E Chirurgia, Bologna, Italy
Graduation Year: 1970

Data Provided by:
James Edward Martin, MD
(410) 749-1282
145 E Carroll St Ste A1
Salisbury, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Miami Sch Of Med, Miami Fl 33101
Graduation Year: 1973

Data Provided by:
Cho Cho, MD
540 Riverside Dr
Salisbury, MD
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Inst Of Med I, Yangon, Myanmar
Graduation Year: 1985

Data Provided by:
Gail Carole Anderson, MD
(410) 341-0005
100 E Carroll St
Salisbury, MD
Specialties
Oncology (Cancer), Radiation Oncology, Diagnostic Radiology
Gender
Female
Education
Medical School: Tufts Univ Sch Of Med, Boston Ma 02111
Graduation Year: 1979
Hospital
Hospital: Peninsula Regional Med Center, Salisbury, Md

Data Provided by:
David Eric Cowall, MD
(410) 749-1282
145 E Carroll St Ste A3
Salisbury, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Oh State Univ Coll Of Med, Columbus Oh 43210
Graduation Year: 1973

Data Provided by:
Panpit Klug
(410) 749-1282
145 E Carroll St
Salisbury, MD
Specialty
Hematology, Medical Oncology

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com